Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.
Immediate postoperative single instillation
non-muscle-invasive bladder cancer
pirarubicin
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
16
11
2020
revised:
07
12
2020
accepted:
08
12
2020
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors.
Sections du résumé
BACKGROUND
BACKGROUND
This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer.
PATIENTS AND METHODS
METHODS
We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival.
RESULTS
RESULTS
Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed.
CONCLUSION
CONCLUSIONS
Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors.
Identifiants
pubmed: 33622912
pii: 35/2/1141
doi: 10.21873/invivo.12360
pmc: PMC8045099
doi:
Substances chimiques
Doxorubicin
80168379AG
pirarubicin
D58G680W0G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1141-1145Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Cancer. 2002 May 1;94(9):2363-8
pubmed: 12015761
Anticancer Res. 2020 Sep;40(9):5295-5299
pubmed: 32878820
J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435
pubmed: 15126782
Eur Urol. 2004 Sep;46(3):336-8
pubmed: 15306104
J Antibiot (Tokyo). 1983 Mar;36(3):312-7
pubmed: 6833151
Transl Androl Urol. 2019 Feb;8(1):76-84
pubmed: 30976571
Int J Urol. 2016 Aug;23(8):640-5
pubmed: 27374472
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Eur Urol. 2009 Sep;56(3):495-503
pubmed: 19560257
Urol Oncol. 2014 Jan;32(1):40.e1-8
pubmed: 23787296
World J Urol. 2018 Jun;36(6):889-895
pubmed: 29387931
J Endourol. 2010 Nov;24(11):1801-6
pubmed: 20932082
J Urol. 2012 May;187(5):1571-6
pubmed: 22425105
Urol Int. 2005;74(3):235-9
pubmed: 15812210
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
JAMA. 2018 May 8;319(18):1880-1888
pubmed: 29801011
World J Urol. 2014 Apr;32(2):525-30
pubmed: 23907663
J Urol. 2012 Dec;188(6):2108-13
pubmed: 23083865
J Urol. 2005 Dec;174(6):2260-2, discussion 2262-3
pubmed: 16280794
Eur Urol. 2016 Feb;69(2):231-44
pubmed: 26091833